StockIQ.techInsulet Corporation (PODD) Stock Analysis
Free AI-powered analysis and research for Insulet Corporation stock
Sector: Healthcare
PODD snapshot
Data as of 3 Nov 2026 close. Updated daily.
Insulet Corporation scores 73/100 on StockIQ's model, which reads as positive signals overall. The price is below its 200-day average and at 13% of its 52-week range, down 51.0% over the past year. Latest reported figures show a profit margin of 12.3%, return on equity of 26.0% and revenue growth of +23.5%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Strong Revenue Growth (23.5%): +8
- Good Profit Margin (12.3%): +5
- Strong Liquidity (2.48 Current Ratio): +8
- Excellent ROE (26.0%): +8
- High P/B (7.30): -5
- Long-term Downtrend: -8
- Severe Underperformance (-51.0% over 1 year): -10
- Low Volume (0.5x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full PODD report
Insulet Corporation (PODD) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze PODD Now →📰 Latest Update
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Wed, October 28, 2026 at 1:00 PM UTC 2 min read
Insulet Corporation (PODD) is set to report its earnings next week, with Wall Street anticipating growth in earnings. This upcoming report is significant for investors as it may indicate the company's financial health and future performance, particularly in the competitive diabetes management market. Positive earnings could bolster investor confidence and potentially influence stock prices in the short term.